Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model
This study supports that subcutaneous GK-1 administered, has an efficacy non-inferior to intravenous administration, well-tolerated with a similar safety profile and therefore offers a less invasive valid treatment alternative.
Authors
- Sergio Sifontes (ORCID: https://orcid.org/0000-0003-1226-8648)
- José Pedraza-Chaverrı́ (ORCID: https://orcid.org/0000-0001-6628-4411)
- Gladis Fragoso (ORCID: https://orcid.org/0000-0003-3885-1858)
- Edda Sciutto (ORCID: https://orcid.org/0000-0001-5608-5355)
- Juan A Hernández-Aceves (ORCID: https://orcid.org/0000-0002-6451-8832)
- Alfredo Cruz‐Gregorio (ORCID: https://orcid.org/0000-0003-0077-5079)
- Ana Karina Aranda‐Rivera (ORCID: https://orcid.org/0000-0002-4095-754X)
- Jacquelynne Cervantes‐Torres (ORCID: https://orcid.org/0000-0002-2610-2860)
- Osiris J Patiño-Chávez
- Tonathiu Rodríguez
- Marisela Hernández (ORCID: https://orcid.org/0000-0001-9995-4688)
- Diego Moctezuma
- Jorge A Peña-Agudelo
Institutions
- Instituto Nacional de Cardiología (MX)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- Vaccine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126814
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México